 This is an extension of our ongoing clinical trial using ex vivo expanded autologous Cytokine-induced killer CIK cells as an adoptive cellular immunotherapy for haematological malignancies. The pre-existing clinical trial targets patient with acute myeloid leukemia or MDS, and relapsed disease post allogeneic transplant. 